Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo

被引:149
|
作者
Xirodimas, D [1 ]
Saville, MK [1 ]
Edling, C [1 ]
Lane, DP [1 ]
Laín, S [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
关键词
p53; p14ARF; Mdm2; ubiquitin; proteasome inhibition;
D O I
10.1038/sj.onc.1204656
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.
引用
收藏
页码:4972 / 4983
页数:12
相关论文
共 50 条
  • [1] Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
    Dimitris Xirodimas
    Mark K Saville
    Charlotte Edling
    David P Lane
    Sonia Laín
    Oncogene, 2001, 20 : 4972 - 4983
  • [2] p53 gene status and expression of p53, MDM2, and p14ARF proteins in ameloblastomas
    Kumamoto, H
    Izutsu, T
    Ohki, K
    Takahashi, N
    Ooya, K
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2004, 33 (05) : 292 - 299
  • [3] P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas
    Chen, Ying
    Wang, Zhao-yan
    Wu, Hao
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (09) : 2227 - 2234
  • [4] P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas
    Ying Chen
    Zhao-yan Wang
    Hao Wu
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 2227 - 2234
  • [5] Methylation of p14ARF and abnormal expression of p53 and mdm2 in colorectal cancer: Role and correlation
    Xiong, Chaoliang
    Li, Jun
    Yan, Lingxian
    Huang, Yuan
    SCIENTIFIC RESEARCH AND ESSAYS, 2010, 5 (13): : 1669 - 1675
  • [6] Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma
    Cheng, Tzu-Hao
    Hsu, Po-Kuei
    Li, Anna Fen-Yau
    Hung, I-Chun
    Huang, Min-Hsiung
    Hsu, Han-Shui
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (11) : 1577 - 1582
  • [7] Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma
    Tzu-Hao Cheng
    Po-Kuei Hsu
    Anna Fen-Yau Li
    I-Chun Hung
    Min-Hsiung Huang
    Han-Shui Hsu
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1577 - 1582
  • [8] p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
    Lindström, MS
    Klangby, U
    Wiman, KG
    ONCOGENE, 2001, 20 (17) : 2171 - 2177
  • [9] Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity
    Cui, Long
    Zhou, Fang
    Chen, Cui
    Wang, Chi Chiu
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [10] p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
    Mikael S Lindström
    Ulf Klangby
    Klas G Wiman
    Oncogene, 2001, 20 : 2171 - 2177